Gapping up
In reaction to strong earnings/guidance:
- CRMT +10.2%, JKS +5.8%, BILI +4.8%, WUBA +4%, MDT +1.9%, ASND +0.9%
M&A news:
- MDCO +28.4% (reports the company is fielding takeover interest from several parties)
- DIOD +4.4% (pending acquisition of Lite-On Semiconductor said to be scrutinized by Chinese regulators, according to Bloomberg)
Other news:
- MYOV +51.8% (Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint)
- NOW +4.1% (to join S&P 500, effective prior to the open on November 21)
- ACHN +2.2% (EMA has granted access to support through the PRIME program for danicopan)
- CLVS +2.1% (continued strength)
- ADS +2.1% (announces Ralph Andretta as new CEO and President, effective February 3, 2020)
- AMC +1.9% (extending late move higher after the WSJ reported that the DOJ will kill the Paramount consent decree which prevented studios form owning exhbitors)
- CNK +0.9% (extending late move higher after the WSJ reported that the DOJ will kill the Paramount consent decree which prevented studios form owning exhbitors)
- TMO +0.7% (to join S&P 100)
Analyst comments:
- BOLD +2.7% (upgraded to Outperform from In-line at Evercore ISI)
- OKTA +2.4% (upgraded to Buy at DA Davidson)
- SPLK +1.4% (initiated with a Buy at DA Davidson)
- GBDC +0.7% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)